Drug intelligence / Profile preview

DFD-04

Development stage: Unknown
Lead developer: Promius Pharma, LLC
Modality: Small Molecules
Administration: Topical

Overview

DFD-04 is a 5% topical itraconazole ointment developed by Dr. Reddy's for the treatment of rosacea. Clinical trials have assessed its efficacy, safety, and tolerability. Pharmacokinetic analysis in studies involved itraconazole and its active metabolite, hydroxyl-itraconazole, confirming that DFD-04 is a formulation containing itraconazole. Itraconazole is a triazole antifungal that inhibits ergosterol synthesis in fungal cell membranes.

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on DFD-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DFD-04.

Explore the full profile